about
ZNF703 gene amplification at 8p12 specifies luminal B breast cancerCarcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulatorsInteraction between two ubiquitin-protein isopeptide ligases of different classes, CBLC and AIP4/ITCH.Loss of heterozygosity at microsatellite markers from region p11-21 of chromosome 8 in microdissected breast tumor but not in peritumoral cells.Nectin-4 is a new histological and serological tumor associated marker for breast cancer.Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes.Comprehensive genome characterization of solitary fibrous tumors using high-resolution array-based comparative genomic hybridization.Genome profiling of ERBB2-amplified breast cancers.Loss, mutation and deregulation of L3MBTL4 in breast cancers.Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markersCandidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profilingCombined translocation with ZNF198-FGFR1 gene fusion and deletion of potential tumor suppressors in a myeloproliferative disorder.Cortical and subventricular zone glioblastoma-derived stem-like cells display different molecular profiles and differential in vitro and in vivo properties.Genome profiling of pancreatic adenocarcinoma.A negative feedback regulatory loop associates the tyrosine kinase receptor ERBB2 and the transcription factor GATA4 in breast cancer cells.Comprehensive profiling of 8p11-12 amplification in breast cancer.Comparative multi-methodological measurement of ERBB2 status in breast cancer.Identification and validation of an ERBB2 gene expression signature in breast cancers.A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.Expression of Genes with Copy Number Alterations and Survival of Patients with Pancreatic Adenocarcinoma.Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers.
P50
Q24293333-D7205D22-B4A1-417B-BAEE-1B594691A788Q24303946-D2337D51-F1A8-4640-A92E-025AEC3A1689Q31109069-037700B3-654C-413C-936B-1B5211DC8007Q31113706-7DFD1EC5-DE36-4488-9A85-657E6C44C7D4Q33283461-7638DFF1-6C0E-4910-A833-9191C7E23E60Q33377270-29E61F15-693C-4F32-AC8C-9139B4320E25Q33403850-104591B3-0534-41BE-8432-D0C078D55181Q33713239-3B97B57A-8E59-441A-8972-C4974DB859DAQ34105097-36E7048F-F87E-4AE0-BC89-24ED3690F26DQ35754783-F5BE2DC5-4378-4C6E-B18B-1E6459D0F979Q37458486-EDD1C00E-A2AB-4B16-A496-3F0CFCA47D73Q38463863-747A5122-7FF3-4576-8517-F60099B649FEQ39459834-3DE56E4B-1476-48C7-A8C8-838C826E9034Q39574924-3F4CF432-1BF3-4E35-816D-D743C7FAB6E3Q39874824-9D0F9D5D-97D8-419D-AD75-7D4F754B87C5Q40335646-91C41D55-F475-45AF-B542-139BA9E1DF8BQ40584056-229A24F8-92B6-4F30-B26B-3FC1821EBFB0Q40595739-53D95067-F3D5-4923-9B5D-6C06E141FF47Q40640693-62E485CD-7413-42E4-9B36-1122FCECB4E8Q40785309-2DF851AB-3C34-48DB-A5C4-D2D390C07642Q42091501-62826500-B495-49D5-A436-F8ED94C8F33F
P50
description
onderzoeker
@nl
name
José Adélaïde
@ast
José Adélaïde
@en
José Adélaïde
@es
José Adélaïde
@nl
José Adélaïde
@sl
type
label
José Adélaïde
@ast
José Adélaïde
@en
José Adélaïde
@es
José Adélaïde
@nl
José Adélaïde
@sl
prefLabel
José Adélaïde
@ast
José Adélaïde
@en
José Adélaïde
@es
José Adélaïde
@nl
José Adélaïde
@sl